港股異動 | 復星醫藥逆市高開7.72% 獲BioNTech授權開發及商業化針對COVID-19疫苗產品
格隆匯3月16日丨復星醫藥(2196.HK)逆市高開7.72%,報21.5港元,暫成交406萬港元,最新總市值551億港元。復星醫藥昨晚發公告稱,公司控股子公司復星醫藥產業與BioNTech簽訂許可協議,BioNTech授權復星醫藥產業區域內(即中國大陸及港澳台地區)獨家開發、商業化基於其專有的mRNA技術平台研發的、針對COVID-19的疫苗產品。復星醫藥產業將根據約定向BioNTech支付至多8500萬美元的許可費,並在約定的銷售提成期間內按該產品年度毛利的35%支付銷售提成。此外,公司投資的合營公司復星凱特的益基利侖賽注射液(擬定)已納入藥品上市註冊優先審評程序,該產品主要用於復發難治性成人大B細胞淋巴瘤的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.